Cyclic voltammetric behaviour of the O2/O2− redox couple at a HMDE and its interaction with nisoldipine
-
Add time:08/28/2019 Source:sciencedirect.com
We have studied the O2/O2− redox couple on the HMDE in DMSO aprotic media, obtaining optimal conditions of both oxygen concentration and scan rate in order to avoid oscillatory phenomena. By choosing the oxygen concentration and scan rate appropriately we obtained well-resolved reversible and reproducible cyclic voltammograms for the O2/O2− redox couple. A ΔEp value of 63.0±5.2 mV for scan rates between 0.6 and 10 V s−1 was obtained. The current ratio, Ipa/Ipc, depended on the scan rate, tending to one as the scan rate increased suggesting that oxygen reduction followed an EC mechanism with the second order superoxide disproportionation reaction as the chemical step. We have found a disproportionation constant value of 4.08×103 M−1 s−1 with a standard deviation of ±208 and a coefficient of variation of 4.8%. Furthermore, we have used the cyclic voltammetric response of the O2/O2− redox couple in order to study the interaction of the dihydropyridine drug nisoldipine with superoxide. With the addition of nisoldipine, the cyclic voltammogram was changed indicating that O2− reacts with nisoldipine within the time scale of the cyclic voltammetry. We have found that superoxide acts as a Brönsted base, deprotonating nisoldipine, and consequently nisoldipine acts by scavenging O2−.
We also recommend Trading Suppliers and Manufacturers of M-NISOLDIPINE (cas 113578-26-0). Pls Click Website Link as below: cas 113578-26-0 suppliers
Prev:Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic−mass spectrometry: applications to pharmacokinetics
Next:Original ContributionsAntihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ContributionsAntihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension08/29/2019
- Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic−mass spectrometry: applications to pharmacokinetics08/27/2019
- Validated LC–MS–MS method for determination of M-NISOLDIPINE (cas 113578-26-0) polymorphs in rat plasma and its application to pharmacokinetic studies08/26/2019
- Molecular and Cellular PharmacologyThe inhibitory effects of M-NISOLDIPINE (cas 113578-26-0) on the 5-hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells via Ca2+ antagonism and antioxidant mechanisms08/25/2019
- Simultaneous determination of M-NISOLDIPINE (cas 113578-26-0) and its three metabolites in rat plasma by liquid chromatography–mass spectrometry08/24/2019
- Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs08/23/2019
- Short communicationStudy of in vitro metabolism of M-NISOLDIPINE (cas 113578-26-0) in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography–mass spectrometry08/22/2019
- Short communicationStudies on separation and pharmacokinetics of M-NISOLDIPINE (cas 113578-26-0) enantiomers in beagle dog plasma by LC/MS/MS08/21/2019
- Original articleOn the dimorphism and the pressure–temperature state diagram of racemic M-NISOLDIPINE (cas 113578-26-0), a dihydropyridine calcium ion antagonistSur le dimorphisme et le diagramme d’état pression-température de la M-NISOLDIPINE (cas 113578-26-0) racémique, une dihydroyridine antagoniste08/20/2019


